BRPI0516992A8 - Método de potencializar modulação imune e inflamatória para célula e terapia de droga - Google Patents

Método de potencializar modulação imune e inflamatória para célula e terapia de droga

Info

Publication number
BRPI0516992A8
BRPI0516992A8 BRPI0516992A BRPI0516992A BRPI0516992A8 BR PI0516992 A8 BRPI0516992 A8 BR PI0516992A8 BR PI0516992 A BRPI0516992 A BR PI0516992A BR PI0516992 A BRPI0516992 A BR PI0516992A BR PI0516992 A8 BRPI0516992 A8 BR PI0516992A8
Authority
BR
Brazil
Prior art keywords
immune
enhancement
cell
drug therapy
inflammatory
Prior art date
Application number
BRPI0516992A
Other languages
English (en)
Inventor
Willing Alison
R Sanberg Paul
B Newman Mary
Davis Sanberg Cyndy
Original Assignee
Univ South Florida
Saneron Ccel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida, Saneron Ccel Therapeutics Inc filed Critical Univ South Florida
Publication of BRPI0516992A publication Critical patent/BRPI0516992A/pt
Publication of BRPI0516992A8 publication Critical patent/BRPI0516992A8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MÉTODO DE POTENCIALIZAR MODULAÇÃO IMUNE E INFLAMATÓRIA PARA CÉLULA E TERAPIA DE DROGA Um método para reparar dano a tecido de animal devido a uma reação de inflamação em um animal tendo as etapas de fornecer células sanguíneas de cordão umbilical (UCBCs) em uma forma farmaceuticamente aceitável; e administrar uma dose suficiente de UCBC em um tempo ótimo, desse modo reduzindo a lesão proveniente da reação inflamatória. Também é fornecido um método de tratar acidente cerebrovascular, inflamação aguda do sistema nervoso central, esclerose múltipla, isquemia do miocárdio, e sofrimento broncopulmonar neonatal. Para determinar o tempo ótimo de administração de UCBCs, é fornecido um kit que contém anticorpos para IL-8 e MCP-1.
BRPI0516992A 2004-10-22 2005-10-24 Método de potencializar modulação imune e inflamatória para célula e terapia de droga BRPI0516992A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62134104P 2004-10-22 2004-10-22
PCT/US2005/038565 WO2006047593A2 (en) 2004-10-22 2005-10-24 Method of potentiating inflammatory and immune modulation for cell and drug therapy

Publications (2)

Publication Number Publication Date
BRPI0516992A BRPI0516992A (pt) 2008-09-30
BRPI0516992A8 true BRPI0516992A8 (pt) 2018-04-03

Family

ID=36228421

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516992A BRPI0516992A8 (pt) 2004-10-22 2005-10-24 Método de potencializar modulação imune e inflamatória para célula e terapia de droga

Country Status (3)

Country Link
US (1) US20060159666A1 (pt)
BR (1) BRPI0516992A8 (pt)
WO (1) WO2006047593A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694038B2 (en) * 2000-04-06 2017-07-04 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
WO2005059115A1 (en) * 2003-12-15 2005-06-30 University Of South Florida Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
US20070178073A1 (en) * 2006-02-01 2007-08-02 Samsung Life Public Welfare Foundation Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease
BRPI0919020B8 (pt) * 2008-09-12 2021-05-25 Cryopraxis Criobiologia Ltda uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
US9795652B2 (en) * 2010-02-25 2017-10-24 University Of South Florida Use of endogenous antioxidant proteins in the treatment of stroke
WO2011143411A1 (en) * 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy for traumatic brain injury
WO2011143415A1 (en) 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
JP6190723B2 (ja) 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US10765706B2 (en) 2015-09-03 2020-09-08 University Of South Florida Method of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers
US20190343882A1 (en) * 2017-01-12 2019-11-14 Duke University Compositions and Methods for the Treatment of Demyelinating Conditions
US20210275583A1 (en) * 2017-01-12 2021-09-09 Duke University Compositions and methods for the treatment of demyelinating conditions
US11278575B2 (en) 2018-07-12 2022-03-22 Duke University Compositions and methods for the treatment of demyelinating conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
AU2001251689A1 (en) * 2000-02-10 2001-08-20 The Research Foundation Of State University Of New York A method for detecting bacterial exacerbations of chronic lung disease
EP1263930A4 (en) * 2000-03-09 2004-07-21 Saneron Ccel Therapeutics Inc HUMAN CORD BLOOD BLOOD AS A SOURCE FOR NEURAL TISSUE FOR HEALING THE BRAIN AND BACK MARK
US20040157253A1 (en) * 2003-02-07 2004-08-12 Millennium Pharmaceuticals, Inc. Methods and compositions for use of inflammatory proteins in the diagnosis and treatment of metabolic disorders
US20040197310A1 (en) * 2003-02-12 2004-10-07 Sanberg Paul R. Compositions and methods for using umbilical cord progenitor cells in the treatment of myocardial infarction
CN1770976A (zh) * 2003-02-13 2006-05-10 人类起源公司 利用脐带血治疗患有疾病、紊乱或状况的个体的用途

Also Published As

Publication number Publication date
WO2006047593A2 (en) 2006-05-04
BRPI0516992A (pt) 2008-09-30
WO2006047593A3 (en) 2009-05-07
US20060159666A1 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
BRPI0516992A8 (pt) Método de potencializar modulação imune e inflamatória para célula e terapia de droga
Kolb et al. Folate deficiency enhances the inflammatory response of macrophages
BR112013004917A2 (pt) terapias de células tronco alogênicas sistêmicas para tratamento de doenças em animais.
CR8380A (es) Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos
BR112013004685A2 (pt) composição e método para reparação e regeneração muscular
BR112014010228A2 (pt) inibidores de reciclagem de ácidos biliares para tratamento da doença de fígado e hipercolemia colestática
EA200100742A1 (ru) Применение 4-h-1-бензопиран-4-оновых производных в качестве ингибиторов пролиферации клеток гладких мышц
UA124239U (uk) Спосіб лікування раку молочної залози
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
NO20080244L (no) Doseringsstyring for prasugrel
Vakili Post-ischemic treatment of pentoxifyline reduces cortical not striatal infarct volume in transient model of focal cerebral ischemia in rat
Zhang et al. Protective effect of electroacupuncture at the Neiguan point in a rabbit model of myocardial ischemia-reperfusion injury
ITMI20001827A1 (it) Medicamento antinfiammatorio
IL182462A0 (en) Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone
Harada et al. Inhibitory effect of iodophenpropit, a selective histamine H3 antagonist, on amygdaloid kindled seizures
MX2022009081A (es) Absorcion celular.
RU2008122964A (ru) Азитромицин для лечения гранулематозных розовых (красных) угрей
CO6190520A2 (es) Metodos para el tratamiento del abuso adiccion y dependencia del alcohol
MXPA05012369A (es) Derivados de benzotiazol y uso de los mismos en el tratamiento de enfermedades relacionadas con el receptor a2a de adenosina.
RU2004128907A (ru) Способ лечения больных хроническим простатитом
WO2008143014A1 (ja) がん治療剤
RU2229293C1 (ru) Лечебно-профилактическое средство для использования в геронтологической практике
Domenico et al. Diet and Muscle Metabolism
CN117137911A (zh) 一种nampt的激活剂及应用
Miserlis et al. Abstract Th0082: Multi-omics Approach of Peripheral Artery Disease Patient Gastrocnemius Describes Disease Progression

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C12N 5/00 (2006.01), A61K 35/51 (2015.01), A61P 29

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL